Back to Search Start Over

KIT oncogene inhibition drives intratumoral macrophage M2 polarization

Authors :
Benjamin L. Green
Teresa S. Kim
Rachel Popow
Vinod P. Balachandran
Jonathan B. Greer
Megan H. Crawley
Peter Besmer
Ferdinand Rossi
Cristina R. Antonescu
Shan Zeng
Michael J. Cavnar
Noah A. Cohen
Adrian M. Seifert
Lee M. Ocuin
Eric C. Sorenson
Ronald P. DeMatteo
Source :
The Journal of Experimental Medicine
Publication Year :
2013
Publisher :
Rockefeller University Press, 2013.

Abstract

Imatinib reduces tumor cell KIT signaling and causes tumor cell apoptosis, which drives TAMs to shift from M1- to M2-like in mouse and human GIST.<br />Tumor-associated macrophages (TAMs) are a major component of the cancer microenvironment. Modulation of TAMs is under intense investigation because they are thought to be nearly always of the M2 subtype, which supports tumor growth. Gastrointestinal stromal tumor (GIST) is the most common human sarcoma and typically results from an activating mutation in the KIT oncogene. Using a spontaneous mouse model of GIST and 57 freshly procured human GISTs, we discovered that TAMs displayed an M1-like phenotype and function at baseline. In both mice and humans, the KIT oncoprotein inhibitor imatinib polarized TAMs to become M2-like, a process which involved TAM interaction with apoptotic tumor cells leading to the induction of CCAAT/enhancer binding protein (C/EBP) transcription factors. In human GISTs that eventually developed resistance to imatinib, TAMs reverted to an M1-like phenotype and had a similar gene expression profile as TAMs from untreated human GISTs. Therefore, TAM polarization depends on tumor cell oncogene activity and has important implications for immunotherapeutic strategies in human cancers.

Details

ISSN :
15409538 and 00221007
Volume :
210
Database :
OpenAIRE
Journal :
Journal of Experimental Medicine
Accession number :
edsair.doi.dedup.....86b7504d0800a9e509d32a5871a92fc2
Full Text :
https://doi.org/10.1084/jem.20130875